1 study found for:    15687361 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Conditions: Breast Cancer;   Hormonreceptor Positive;   Her2-normal;   Postneoadjuvant Treatment With CDK 4/6 Inhibitor;   CPS-EG Score
Interventions: Drug: Palbociclib PD-0332991;   Drug: Placebo

Indicates status has not been verified in more than two years